Skip to main content
SpringerLink
Log in
Book cover

Chronic Lymphocytic Leukemia pp 173–184Cite as

Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1881))

Abstract

Over recent decades it has become increasingly apparent that malignant cells, including chronic lymphocytic leukemia (CLL) cells, do not exist in isolation. Rather they coalesce with numerous “normal” cells of the body and, in the case of CLL, inhabit key immunological niches within secondary lymphoid organs (SLO), where a plethora of stromal and immune cells mediate their growth and survival. With the advent and approval of targeted immune therapies such as monoclonal antibodies (mAb), which elicit their efficacy by engaging immune-mediated effector mechanisms, it is important to develop accurate methods to measure their activities. Here, we describe a series of reliable assays capable of measuring important antibody-mediated effector functions: antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC) that measure these immune activities.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Glennie MJ, Johnson PWM (2000) Clinical trials of antibody therapy. Immunol Today 21(8):403–410. https://doi.org/10.1016/s0167-5699(00)01669-8

    Article  CAS  PubMed  Google Scholar 

  2. Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95(1):135–143. https://doi.org/10.3324/haematol.2008.001628

    Article  CAS  PubMed  Google Scholar 

  3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. https://doi.org/10.1056/NEJMoa011795

    Article  CAS  PubMed  Google Scholar 

  4. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825–2833. https://doi.org/10.1200/jco.1998.16.8.2825

    Article  CAS  PubMed  Google Scholar 

  5. Glennie MJ, French RR, Cragg MS, Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44(16):3823–3837

    Article  CAS  Google Scholar 

  6. Williams EL, Tutt AL, Beers SA, French RR, Chan CHT, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ (2013) Immunotherapy targeting inhibitory Fc gamma receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 191(8):4130–4140. https://doi.org/10.4049/jimmunol.1301430

    Article  CAS  PubMed  Google Scholar 

  7. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PWM, Cragg MS, Glennie MJ (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118(9):2530–2540. https://doi.org/10.1182/blood-2011-01-330357

    Article  PubMed  Google Scholar 

  8. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6(4):443–446

    Article  CAS  Google Scholar 

  9. Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HTC, Li Z-C, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PWM, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS (2015) Antagonistic FcγRIIB antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell 27

    Article  CAS  Google Scholar 

  10. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CHT, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117(17):4519–4529. https://doi.org/10.1182/blood-2010-07-296913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJS, Poppema S, Klein C, Umana P (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22):4393–4402. https://doi.org/10.1182/blood-2009-06-225979

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao FF, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699–713. https://doi.org/10.1016/j.cell.2010.07.044

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He L-Z, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH (2017) Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. Cancer Cell 32(6):777–791.e776. https://doi.org/10.1016/j.ccell.2017.11.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors would like to thank and acknowledge all members of the Antibody and Vaccine group, past and present, who together have helped develop these protocols and provide antibody for the studies reported. The work was supported by CRUK grants C1477/A10834, C1477/A20537, C34999/A18087, and C328/A25139; Bloodwise grant 12050 and KKLF grant KKL981.

Author information

Author notes

  1. M. J. Carter, L. N. Dahal, K. L. S. Cleary, and M. J. E. Marshall contributed equally to this work.

Authors and Affiliations

  1. Antibody and Vaccine Group, Centre for Cancer Immunology, Cancer Sciences Unit, Faculty of Medicine, Southampton General Hospital, Southampton, UK

    M. J. Carter, L. N. Dahal, K. L. S. Cleary, M. J. E. Marshall, R. R. French, S. A. Beers & M. S. Cragg

Authors
  1. M. J. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. N. Dahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. L. S. Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. J. E. Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. R. French
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. A. Beers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. S. Cragg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. S. Cragg .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

    Sami N. Malek

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Carter, M.J. et al. (2019). Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. In: Malek, S. (eds) Chronic Lymphocytic Leukemia. Methods in Molecular Biology, vol 1881. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8876-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8876-1_14

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8875-4

  • Online ISBN: 978-1-4939-8876-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation